(Q51977193)

English

Open label, multicenter, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer's disease.

scientific article published on 7 March 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 April 2018

http://europepmc.org/abstract/MED/17345042

Open label, multicenter, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer's disease. (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 April 2018

http://europepmc.org/abstract/MED/17345042

1

object named as

Brian R Ott

1 reference

Europe PubMed Central

PubMed publication ID

19 April 2018

http://europepmc.org/abstract/MED/17345042

author name string

Lesley M Blake

2

1 reference

Europe PubMed Central

PubMed publication ID

19 April 2018

http://europepmc.org/abstract/MED/17345042

Ethel Kagan

3

1 reference

Europe PubMed Central

PubMed publication ID

19 April 2018

http://europepmc.org/abstract/MED/17345042

Malca Resnick

4

1 reference

Europe PubMed Central

PubMed publication ID

19 April 2018

http://europepmc.org/abstract/MED/17345042

Memantine MEM-MD-11AB Study Group

5

1 reference

Europe PubMed Central

PubMed publication ID

19 April 2018

http://europepmc.org/abstract/MED/17345042

publication date

7 March 2007

1 reference

Europe PubMed Central

PubMed publication ID

19 April 2018

http://europepmc.org/abstract/MED/17345042

Journal of Neurology

1 reference

Europe PubMed Central

PubMed publication ID

19 April 2018

http://europepmc.org/abstract/MED/17345042

254

1 reference

Europe PubMed Central

PubMed publication ID

19 April 2018

http://europepmc.org/abstract/MED/17345042

3

1 reference

Europe PubMed Central

PubMed publication ID

19 April 2018

http://europepmc.org/abstract/MED/17345042

351-358

1 reference

Europe PubMed Central

PubMed publication ID

19 April 2018

http://europepmc.org/abstract/MED/17345042

https://scigraph.springernature.com/pub.10.1007/s00415-006-0374-x

0 references

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1007%2FS00415-006-0374-X

21 January 2018

Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group.

1 reference

https://api.crossref.org/works/10.1007%2FS00415-006-0374-X

21 January 2018

A new rating scale for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1007%2FS00415-006-0374-X

21 January 2018

An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17345042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study

1 reference

https://pubmed.ncbi.nlm.nih.gov/17345042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia

1 reference

https://pubmed.ncbi.nlm.nih.gov/17345042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/17345042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine).

1 reference

https://pubmed.ncbi.nlm.nih.gov/17345042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist--a review of preclinical data

1 reference

https://pubmed.ncbi.nlm.nih.gov/17345042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

“Mini-mental state”

1 reference

https://pubmed.ncbi.nlm.nih.gov/17345042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence

1 reference

https://pubmed.ncbi.nlm.nih.gov/17345042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/17345042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Memantine in moderate-to-severe Alzheimer's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/17345042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/17345042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Galantamine provides sustained benefits in patients with 'advanced moderate' Alzheimer's disease for at least 12 months

1 reference

https://pubmed.ncbi.nlm.nih.gov/17345042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/17345042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17345042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Glutamate and the glutamate receptor system: a target for drug action

1 reference

https://pubmed.ncbi.nlm.nih.gov/17345042

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00415-006-0374-X

1 reference

Europe PubMed Central

PubMed publication ID

19 April 2018

http://europepmc.org/abstract/MED/17345042

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 April 2018

http://europepmc.org/abstract/MED/17345042

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51977193&oldid=1398676956"